Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting
Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…Abstract Number: 2028 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologic Agents In Adult-Onset Still’s Disease: A Long-Term Follow-Up Of 19 Patients At a Single Referral Center
Background/Purpose: No data comparing the long-term outcome of Adult-Onset Still’s Disease (AOSD) patients treated with different biological drugs is currently available. We evaluated the efficacy…Abstract Number: 1415 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
Background/Purpose: A large-scale post-marketing surveillance (PMS) has been implemented to evaluate the safety and effectiveness on the use of intravenous abatacept (ABT) in Japanese patients…Abstract Number: 411 • 2013 ACR/ARHP Annual Meeting
Differential Effects of biologics On The Removal Of Amyloid Deposition Between The Kidney and Gastric Tract Of Amyloid A Amyloidosis Patients With Rheumatoid Arthritis
Background/Purpose: Several biologics therapy reportedly regress gastric amyloid deposition in amyloid A (AA) amyloidosis patients with rheumatoid arthritis (RA), but it is uncertain whether the…Abstract Number: 2484 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis
Background/Purpose: TNFα blockers have been shown to produce immunogenecity in patients with rheumatoid arthritis, spondyloarthrritis and inflammatory bowel diseases. Data on the induction of anti-drug…Abstract Number: 1942 • 2013 ACR/ARHP Annual Meeting
Ultrasound Shows Tenosynovitis to be Frequently Present as Well As Sensitive to Change in RA Patients On Biologic Medication
Background/Purpose: Ultrasound (US) (grey scale (GS) and power Doppler (PD)) is a sensitive tool for examination of tenosynovitis in patients with rheumatoid arthritis (RA). The…Abstract Number: 1379 • 2013 ACR/ARHP Annual Meeting
Differential Effects Of TNF Inhibitors, Anti-IL-6 Receptor Antibody and CTLA4-Ig On Human Monocytes
Background/Purpose: Biological agents inhibiting proinflammatory cytokines, especially IL-6 and TNFa, have brought a great impact in the treatment of rheumatoid arthritis (RA). In addition, CTLA4-Ig…Abstract Number: 415 • 2013 ACR/ARHP Annual Meeting
Stability Of Carotid Intima Media Thickness and No Plaque Formation In Inflammatory Arthritis Patients On Biologics Over One Year
Background/Purpose: Carotid intima media (cIMT) measurement is a validated surrogate measure of cardiovascular (CV) disease. Our aim was to evaluate baseline and follow-up cIMTs in…Abstract Number: 2391 • 2013 ACR/ARHP Annual Meeting
Pathogenic Pro-Inflammatory Cytokine Production Induced By Synovial Fluid From RA Patients Is Related To Levels Of Endogenous TLR4 Ligands and Is Blocked By a Novel Therapeutic Anti-Human TLR4 Monoclonal Antibody, NI-0101
Background/Purpose: Deregulation of Toll-Like Receptor 4 (TLR4) signaling is thought to play a role in the pathogenesis of certain autoimmune diseases. In rheumatoid arthritis (RA),…Abstract Number: 1750 • 2013 ACR/ARHP Annual Meeting
Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients
Background/Purpose: To evaluate short and long-term response to biological therapy in uveitis associated to Behçet´s syndrome refractory to standard systemic treatment. Methods: Multicenter study of…Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…Abstract Number: 2375 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Glucocorticoids Sparing Effect: The Spare-1 Study
Background/Purpose: Although glucocorticoids (GCs) may be appropriate in rheumatoid arthritis (RA), there is general agreement that GCs sparing is desirable. The safety of GCs is…Abstract Number: 1733 • 2013 ACR/ARHP Annual Meeting
Early and Sustained Improvement In Pain and Physical Function As Measured By Visual Analog Scale and Short Form-36 Physical Component Summary Score In Rheumatoid Arthritis Patients Treated With Mavrilimumab, An Investigational Anti-GM-CSFR-Alpha Monoclonal Antibody, In a Phase 2a Study
Background/Purpose: Rheumatoid arthritis (RA) is associated with significant pain and loss of physical function. We evaluated self-reported pain and physical function in adults patients with…Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting
Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?
Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…
ACR Meeting Abstracts